This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aviles, P.
Right arrow Articles by Gargallo-Viola, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aviles, P.
Right arrow Articles by Gargallo-Viola, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2333-2340, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Pharmacokinetics-Pharmacodynamics of a Sordarin Derivative (GM 237354) in a Murine Model of Lethal Candidiasis

P. Aviles,1 C. Falcoz,2,dagger R. San Roman,1 and D. Gargallo-Viola1,*

Glaxo Wellcome S.A., Parque Tecnológico de Madrid, 28760 Tres Cantos, Madrid, Spain,1 and Glaxo Wellcome R&D, Greenford, Middlesex, UB6 0HE, United Kingdom2

Received 5 November 1999/Returned for modification 27 February 2000/Accepted 10 June 2000

Sordarins are a new class of antifungal agents which selectively inhibit fungal protein synthesis (FPS) by impairing the function of elongation factor 2. The present study investigates possible correlations between sordarin pharmacokinetic (PK) properties and therapeutic efficacy, based on a murine model of invasive systemic candidiasis, and provides a rationale for dose selection in the first study of efficacy in humans. A significant correlation between PK parameters and the in vivo activity of GM 237354, taken as a representative FPS inhibitor, was demonstrated in a murine model of lethal systemic candidiasis. Area under the concentration-time curve (AUC) and maximum concentration of drug in serum (Cmax) over 24 h were determined after a single GM 237354 subcutaneous (s.c.) dose (50 mg/kg of body weight) in healthy animals (no significant PK changes with infection were observed for other sordarin derivatives). These results have been used to simulate PK profiles obtained after several doses and/or schedules in animal therapy. A PK-pharmacodynamic (PD) parameter such as the time that serum drug concentrations remain above the MIC (t > MIC) was also determined. Treatment efficacies were evaluated in terms of the area under the survival time curve (AUSTC), using Kaplan-Meier survival analysis and in terms of kidney fungal burden (log CFU/gram) after s.c. doses of 2.5, 5, 10, 20, and 40 mg/kg every 4, 8, or 12 h (corresponding to total daily doses of 5 to 240 mg/kg). The results show all treatments to significantly prolong survival versus that of infected and nontreated controls (P < 0.05). Relationships between simulated PK and PK-PD parameters and efficacy were explored. A good correlation independent of the dosing interval was observed with AUC (but not Cmax or t > MIC) and both AUSTC and kidney burden. Following repeated dosing every 8 h, AUC50 (AUC at which 50% of the maximum therapeutic efficacy is obtained) was estimated as 21.7 and 37.1 µg · h/ml (total concentrations) for AUSTC and kidney burden using a sigmoid Emax and an inhibitory sigmoid Emax PK-PD model, respectively. For an efficacy target of 90% survival, AUC was predicted as 67 µg · h/ml. We conclude that the PK-PD approach is useful for evaluating relationships between PK parameters and efficacy in antifungal research. Moreover, the results obtained with this approach could be successfully applied to clinical studies.

* Corresponding author. Mailing address: GlaxoWellcome S.A., Parque Tecnológico de Madrid, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain. Phone: 34-91-8070301. Fax: 34-91-807.05.95. E-mail: DGV28867{at}glaxowellcome.co.uk.

dagger Present address: GlaxoWellcome S.p.A., 37137 Verona, Italy.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2333-2340, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • te Dorsthorst, D. T. A., Verweij, P. E., Meis, J. F. G. M., Mouton, J. W. (2005). Efficacy and Pharmacodynamics of Flucytosine Monotherapy in a Nonneutropenic Murine Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 49: 4220-4226 [Abstract] [Full Text]  
  • Kamai, Y., Kakuta, M., Shibayama, T., Fukuoka, T., Kuwahara, S. (2005). Antifungal Activities of R-135853, a Sordarin Derivative, in Experimental Candidiasis in Mice. Antimicrob. Agents Chemother. 49: 52-56 [Abstract] [Full Text]  
  • Andes, D. (2003). In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. Antimicrob. Agents Chemother. 47: 1179-1186 [Full Text]  
  • Jimenez, E., Martinez, A., Aliouat, E. M., Caballero, J., Dei-Cas, E., Gargallo-Viola, D. (2002). Therapeutic Efficacies of GW471552 and GW471558, Two New Azasordarin Derivatives, against Pneumocystosis in Two Immunosuppressed-Rat Models. Antimicrob. Agents Chemother. 46: 2648-2650 [Abstract] [Full Text]  
  • Martinez, A., Ferrer, S., Santos, I., Jimenez, E., Sparrowe, J., Regadera, J., De Las Heras, F. G., Gargallo-Viola, D. (2001). Antifungal Activities of Two New Azasordarins, GW471552 and GW471558, in Experimental Models of Oral and Vulvovaginal Candidiasis in Immunosuppressed Rats. Antimicrob. Agents Chemother. 45: 3304-3309 [Abstract] [Full Text]  
  • Herreros, E., Almela, M. J., Lozano, S., Gomez De Las Heras, F., Gargallo-Viola, D. (2001). Antifungal Activities and Cytotoxicity Studies of Six New Azasordarins. Antimicrob. Agents Chemother. 45: 3132-3139 [Abstract] [Full Text]  
  • Aviles, P., Falcoz, C., Guillen, M. J., San Roman, R., Gomez De Las Heras, F., Gargallo-Viola, D. (2001). Correlation between In Vitro and In Vivo Activities of GM 237354, a New Sordarin Derivative, against Candida albicans in an In Vitro Pharmacokinetic-Pharmacodynamic Model and Influence of Protein Binding. Antimicrob. Agents Chemother. 45: 2746-2754 [Abstract] [Full Text]  
  • Aviles, P., Pateman, A., San Roman, R., Guillen, M. J., Gomez De Las Heras, F., Gargallo-Viola, D. (2001). Animal Pharmacokinetics and Interspecies Scaling of Sordarin Derivatives following Intravenous Administration. Antimicrob. Agents Chemother. 45: 2787-2792 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Mellado, E., Díaz-Guerra, T. M., Monzón, A., Rodríguez-Tudela, J. L. (2001). Azasordarins: Susceptibility of Fluconazole-Susceptible and Fluconazole-Resistant Clinical Isolates of Candida spp. to GW 471558. Antimicrob. Agents Chemother. 45: 1905-1907 [Abstract] [Full Text]  
  • Martinez, A., Regadera, J., Jimenez, E., Santos, I., Gargallo-Viola, D. (2001). Antifungal Efficacy of GM237354, a Sordarin Derivative, in Experimental Oral Candidiasis in Immunosuppressed Rats. Antimicrob. Agents Chemother. 45: 1008-1013 [Abstract] [Full Text]  
  • Dominguez, J. M., Martin, J. J. (2001). Identification of a Putative Sordarin Binding Site in Candida albicans Elongation Factor 2 by Photoaffinity Labeling. J. Biol. Chem. 276: 31402-31407 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»